Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer

被引：12

作者：

Szabados, Bernadett ^{[1
]}

Prendergast, Aaron ^{[2
]}

Jackson-Spence, Francesca ^{[1
]}

Choy, Julia ^{[1
]}

Powles, Thomas ^{[1
]}

机构：

[1] Queen Mary Univ London, Barts Expt Canc Med Ctr, Barts Canc Inst, London, England

[2] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst CRUK Ctr Excellence, London EC1M 6BQ, England

来源：

EUROPEAN UROLOGY ONCOLOGY | 2021年 / 4卷 / 06期

关键词：

Urothelial carcinoma; Bladder; Immune checkpoint inhibitor; Chemotherapy; First-line treatment; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; OPEN-LABEL; MULTICENTER; CHEMOTHERAPY; CARCINOMA; PEMBROLIZUMAB; ATEZOLIZUMAB;

D O I：

10.1016/j.euo.2021.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors are the standard-of-care front-line treatment option for PD-L1-positive, cisplatin-ineligible metastatic urothelial carcinoma. The data supporting this are based on two single-arm trials. Randomised trials to confirm these findings and test new combinations have recently been performed. It was hoped that these trials would clarify some of the previous uncertainties. In this report we summarise the findings from these trials and perform a combined analysis. The results show that immune checkpoint inhibitor monotherapy is not superior to chemotherapy as things currently stand. The chemoimmunotherapy combination shows a probable efficacy signal, but this appears to be insufficient to change practice. Patient summary: In this report, we summarise the outcomes of three recent trials that investigated immunotherapy (IMT) on its own and combined with chemotherapy (CT) for patients with metastatic bladder cancer who had not previously received any treatment. We show that IMT on its own is not better than CT for these patients. There is a sign that combined CT and IMT probably has a benefit, but it does not seem to be large enough to justify a change in treatment recommendations. (C) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

引用

页码：943 / 947

页数：5

共 15 条

[1] Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 [J].

Alva, A. ;

Csoszi, T. ;

Ozguroglu, M. ;

Matsubara, N. ;

Geczi, L. ;

Cheng, S. Y-S. ;

Fradet, Y. ;

Oudard, S. ;

Vulsteke, C. ;

Morales Barrera, R. ;

Flechon, A. ;

Gunduz, S. ;

Loriot, Y. ;

Rodriguez-Vida, A. ;

Mamtani, R. ;

Yu, E. Y. ;

Nam, K. ;

Imai, K. ;

Moreno, B. H. ;

Powles, T. B. .

ANNALS OF ONCOLOGY, 2020, 31 :S1155-S1155

[2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[5] A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now [J].

Bellmunt, Joaquin ;

Powles, Thomas ;

Vogelzang, Nicholas J. .

CANCER TREATMENT REVIEWS, 2017, 54 :58-67

[6] Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial [J].

Galsky, Matthew D. ;

Arranz Arija, Jose Angel ;

Bamias, Aristotelis ;

Davis, Ian D. ;

De Santis, Maria ;

Kikuchi, Eiji ;

Garcia-del-Muro, Xavier ;

De Giorgi, Ugo ;

Mencinger, Marina ;

Izumi, Kouji ;

Panni, Stefano ;

Gumus, Mahmut ;

Ozguroglu, Mustafa ;

Kalebasty, Arash Rezazadeh ;

Park, Se Hoon ;

Alekseev, Boris ;

Schutz, Fabio A. ;

Li, Jian-Ri ;

Ye, Dingwei ;

Vogelzang, Nicholas J. ;

Bernhard, Sandrine ;

Tayama, Darren ;

Mariathasan, Sanjeev ;

Mecke, Almut ;

Thastrom, AnnChristine ;

Grande, Enrique .

LANCET, 2020, 395 (10236) :1547-1557

[7] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[8]

MANTEL N, 1959, JNCI-J NATL CANCER I, V22, P719

[9] TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells [J].

Mariathasan, Sanjeev ;

Turley, Shannon J. ;

Nickles, Dorothee ;

Castiglioni, Alessandra ;

Yuen, Kobe ;

Wang, Yulei ;

Kadel, Edward E., III ;

Koeppen, Hartmut ;

Astarita, Jillian L. ;

Cubas, Rafael ;

Jhunjhunwala, Suchit ;

Banchereau, Romain ;

Yang, Yagai ;

Guan, Yinghui ;

Chalouni, Cecile ;

Ziai, James ;

Senbabaoglu, Yasin ;

Santoro, Stephen ;

Sheinson, Daniel ;

Hung, Jeffrey ;

Giltnane, Jennifer M. ;

Pierce, Andrew A. ;

Mesh, Kathryn ;

Lianoglou, Steve ;

Riegler, Johannes ;

Carano, Richard A. D. ;

Eriksson, Pontus ;

Hoglund, Mattias ;

Somarriba, Loan ;

Halligan, Daniel L. ;

van der Heijden, Michiel S. ;

Loriot, Yohann ;

Rosenberg, Jonathan E. ;

Fong, Lawrence ;

Mellman, Ira ;

Chen, Daniel S. ;

Green, Marjorie ;

Derleth, Christina ;

Fine, Gregg D. ;

Hegde, Priti S. ;

Bourgon, Richard ;

Powles, Thomas .

NATURE, 2018, 554 (7693) :544-+

[10] Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma [J].

McDermott, David F. ;

Huseni, Mahrukh A. ;

Atkins, Michael B. ;

Motzer, Robert J. ;

Rini, Brian I. ;

Escudier, Bernard ;

Fong, Lawrence ;

Joseph, Richard W. ;

Pal, Sumanta K. ;

Reeves, James A. ;

Sznol, Mario ;

Hainsworth, John ;

Rathmell, W. Kimryn ;

Stadler, Walter M. ;

Hutson, Thomas ;

Gore, Martin E. ;

Ravaud, Alain ;

Bracarda, Sergio ;

Suarez, Cristina ;

Danielli, Riccardo ;

Gruenwald, Viktor ;

Choueiri, Toni K. ;

Nickles, Dorothee ;

Jhunjhunwala, Suchit ;

Piault-Louis, Elisabeth ;

Thobhani, Alpa ;

Qiu, Jiaheng ;

Chen, Daniel S. ;

Hegde, Priti S. ;

Schiff, Christina ;

Fine, Gregg D. ;

Powles, Thomas .

NATURE MEDICINE, 2018, 24 (06) :749-+

← 1 2 →